MAPLE GROVE, Minn., Aug. 24, 2026 /PRNewswire/ — RPC is pleased to announce the successful acquisition of the Peracidin^® product line from Angelini Pharma, expanding our portfolio of high-quality peroxyacetic/peracetic acid (PAA) sterilants for dialysis, water treatment and life science applications.

This strategic acquisition reinforces our long-term commitment to providing reliable and trusted industry-leading products, exceptional customer support, and uninterrupted supply to healthcare providers and distribution partners worldwide.

“The acquisition of the Peracidin^® product line represents an important milestone in RPC’s continued growth and further strengthens our leadership in peracetic acid technologies and innovative dialysis solutions, while broadening our ability to serve customers across complementary healthcare and water treatment markets,” said Vern Taaffe, CEO. “We are honored to welcome Peracidin^® customers to RPC and look forward to building on the product’s strong legacy by providing exceptional service, reliable supply, and the quality all of our customers have come to expect.”

For additional information about Peracidin® or Micro-X®, please contact RPC at orders@rpc-rabrenco.com, or call US: (800) 647-3873 or International: (520) 888-5550

About RPC

RPC is a leading manufacturer and provider of innovative products, technical expertise, and specialized solutions for the dialysis industry, supporting healthcare providers and distribution partners worldwide. Drawing on decades of dialysis experience, RPC develops, manufactures, and supplies high-quality products that improve patient care and address the technical needs of dialysis providers. The company maintains an active commitment to advancing industry standards through participation in the Association for the Advancement of Medical Instrumentation (AAMI), including AAMI Corporate and Renal Disease and Detoxification (RDD) Committee membership, and its employees are active members of AAMI and the National Association of Nephrology Technicians/Technologists (NANT). Headquartered in Tucson, Arizona, with additional offices and production in Maple Grove, MN, RPC serves customers and distribution partners worldwide with a comprehensive portfolio of products backed by technical expertise, responsive customer service, and a commitment to quality. For more information, visit https://www.rpc-rabrenco.com.

About Angelini Pharma

Angelini Pharma is an international pharmaceutical company and part of Angelini Industries. The company researches, develops, and commercializes health solutions with a particular focus on Brain Health, including mental health and epilepsy, and the Consumer market. Founded in Italy at the beginning of the twentieth century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are commercialized in over 70 countries through strategic alliances with leading international pharmaceutical groups. For more information on Angelini Pharma, visit https://www.angelinipharma.com.

Media Contact: Stuart Geller, Sgeller@rpc-rabrenco.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rpc-acquires-peracidin-product-line-302858464.html

SOURCE RPC